Status:
COMPLETED
The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Hyperphosphatemia
Eligibility:
All Genders
18-80 years
Brief Summary
Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (M...
Eligibility Criteria
Inclusion
- hemodialysis with duration\>3 months serum P level \>5.5 mg/dl serum Ca\>8 mg/dl.
Exclusion
- Mg level \>3 mg/dl
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01854437
Start Date
June 1 2012
End Date
December 1 2012
Last Update
May 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shiraz University Hemodialysis Center
Shiraz, Fars, Iran, o98-711